These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 33773207)

  • 1. The AMPK modulator metformin as adjunct to methotrexate in patients with rheumatoid arthritis: A proof-of-concept, randomized, double-blind, placebo-controlled trial.
    Abdallah MS; Alarfaj SJ; Saif DS; El-Naggar ME; Elsokary MA; Elsawah HK; Abdelsattar Zaki S; Wahsh EA; Abo Mansour HE; Mosalam EM
    Int Immunopharmacol; 2021 Jun; 95():107575. PubMed ID: 33773207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Adalimumab plus methotrexate for the treatment of rheumatoid arthritis: a multi-center randomized, double-blind, placebo-controlled clinical study.].
    Huang F; Zhang FC; Bao CD; Tao Y; Gu JR; Xu JH; Zhu P; Xu HJ; Zhang ZY; Zhao DB; Wu DH
    Zhonghua Nei Ke Za Zhi; 2009 Nov; 48(11):916-21. PubMed ID: 20079321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, double-blind, and placebo-controlled multicenter clinical trial of a novel cytotoxic T-lymphocyte antigen-4 fusion protein, Leining, in Chinese active rheumatoid arthritis patients with an inadequate response to methotrexate.
    Fan W; Zhao DB; Hu SX; Xu HJ; Zhang X; Zhang MJ; Chen ZW; Zhang FX; Zhu P; Li XF; Bi LQ; Zhou B; Bao CD
    Rheumatol Int; 2014 Nov; 34(11):1519-27. PubMed ID: 24671501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy.
    Li Z; Zhang F; Kay J; Fei K; Han C; Zhuang Y; Wu Z; Hsia EC
    Int J Rheum Dis; 2016 Nov; 19(11):1143-1156. PubMed ID: 26259617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.
    Weisman MH; Moreland LW; Furst DE; Weinblatt ME; Keystone EC; Paulus HE; Teoh LS; Velagapudi RB; Noertersheuser PA; Granneman GR; Fischkoff SA; Chartash EK
    Clin Ther; 2003 Jun; 25(6):1700-21. PubMed ID: 12860493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double-blind, placebo/active-controlled, dose-ranging study.
    Weinblatt ME; Mease P; Mysler E; Takeuchi T; Drescher E; Berman A; Xing J; Zilberstein M; Banerjee S; Emery P
    Arthritis Rheumatol; 2015 Oct; 67(10):2591-600. PubMed ID: 26138593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial.
    Fleischmann R; Pangan AL; Song IH; Mysler E; Bessette L; Peterfy C; Durez P; Ostor AJ; Li Y; Zhou Y; Othman AA; Genovese MC
    Arthritis Rheumatol; 2019 Nov; 71(11):1788-1800. PubMed ID: 31287230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone.
    Kremer JM; Cohen S; Wilkinson BE; Connell CA; French JL; Gomez-Reino J; Gruben D; Kanik KS; Krishnaswami S; Pascual-Ramos V; Wallenstein G; Zwillich SH
    Arthritis Rheum; 2012 Apr; 64(4):970-81. PubMed ID: 22006202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis.
    Weinblatt ME; McInnes IB; Kremer JM; Miranda P; Vencovsky J; Guo X; White WI; Ryan PC; Godwood A; Albulescu M; Close D; Burmester GR
    Arthritis Rheumatol; 2018 Jan; 70(1):49-59. PubMed ID: 28941039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Levilimab in Combination with Methotrexate in Patients with Active Rheumatoid Arthritis: 56-Week Results of Phase III Randomized Double-Blind Placebo-Controlled Trial SOLAR.
    Mazurov VI; Nasonov EL; Lila AM; Korolev MA; Prystrom AM; Kundzer EV; Soroka NF; Kastanayan AA; Povarova TV; Plaksina TV; Antipova OV; Krechikova DG; Smakotina SA; Tciupa OA; Puntus EV; Raskina TA; Shilova LN; Kropotina TV; Nesmeyanova OB; Popova TA; Vinogradova IB; Dokukina EA; Plotnikova AV; Pukhtinskaia PS; Zinkina-Orikhan AV; Linkova YN; Eremeeva AV; Lutckii AA
    Dokl Biochem Biophys; 2024 Oct; 518(1):403-416. PubMed ID: 39196526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial.
    Taylor PC; Saurigny D; Vencovsky J; Takeuchi T; Nakamura T; Matsievskaia G; Hunt B; Wagner T; Souberbielle B;
    Arthritis Res Ther; 2019 Apr; 21(1):101. PubMed ID: 30999929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized, double-blind, placebo-controlled, comparative study of human anti-TNF antibody adalimumab in combination with methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis.
    Chen DY; Chou SJ; Hsieh TY; Chen YH; Chen HH; Hsieh CW; Lan JL
    J Formos Med Assoc; 2009 Apr; 108(4):310-9. PubMed ID: 19369178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid onset of efficacy predicts response to therapy with certolizumab plus methotrexate in patients with active rheumatoid arthritis.
    Kang YM; Park YE; Park W; Choe JY; Cho CS; Shim SC; Bae SC; Suh CH; Cha HS; Koh EM; Song YW; Yoo B; Lee SS; Park MC; Lee SH; Arendt C; Koetse W; Lee SK
    Korean J Intern Med; 2018 Nov; 33(6):1224-1233. PubMed ID: 29294598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial.
    Rigby W; Tony HP; Oelke K; Combe B; Laster A; von Muhlen CA; Fisheleva E; Martin C; Travers H; Dummer W
    Arthritis Rheum; 2012 Feb; 64(2):350-9. PubMed ID: 21905001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1).
    Westhovens R; Taylor PC; Alten R; Pavlova D; Enríquez-Sosa F; Mazur M; Greenwald M; Van der Aa A; Vanhoutte F; Tasset C; Harrison P
    Ann Rheum Dis; 2017 Jun; 76(6):998-1008. PubMed ID: 27993829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
    Cohen SB; Emery P; Greenwald MW; Dougados M; Furie RA; Genovese MC; Keystone EC; Loveless JE; Burmester GR; Cravets MW; Hessey EW; Shaw T; Totoritis MC;
    Arthritis Rheum; 2006 Sep; 54(9):2793-806. PubMed ID: 16947627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase 2a, randomized, double-blind, placebo-controlled trial of the efficacy and safety of the oral gonadotropin-releasing hormone antagonist, ASP1707, in postmenopausal female patients with rheumatoid arthritis taking methotrexate.
    Takeuchi T; Tanaka Y; Higashitani C; Iwai M; Komatsu K; Akazawa R; Lademacher C
    Mod Rheumatol; 2021 Jan; 31(1):53-60. PubMed ID: 32075475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Therapy.
    Kremer JM; Emery P; Camp HS; Friedman A; Wang L; Othman AA; Khan N; Pangan AL; Jungerwirth S; Keystone EC
    Arthritis Rheumatol; 2016 Dec; 68(12):2867-2877. PubMed ID: 27389975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: a randomized, controlled trial.
    Lambert CM; Sandhu S; Lochhead A; Hurst NP; McRorie E; Dhillon V
    Arthritis Rheum; 2004 Feb; 50(2):364-71. PubMed ID: 14872477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: an open-label extension of a randomized, double-blind, placebo-controlled trial.
    Hara M; Ishiguro N; Katayama K; Kondo M; Sumida T; Mimori T; Soen S; Nagai K; Yamaguchi T; Yamamoto K;
    Mod Rheumatol; 2014 May; 24(3):410-8. PubMed ID: 24252050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.